首页> 美国卫生研究院文献>other >Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN Patients with Intermittent Claudication Injected with ALDH Bright Cells (PACE) Trial
【2h】

Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN Patients with Intermittent Claudication Injected with ALDH Bright Cells (PACE) Trial

机译:细胞疗法对周围动脉疾病运动表现和肢体灌注的评估:间歇性lau行的CCTRN患者注射ALDH亮细胞(PACE)试验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundAtherosclerotic peripheral artery disease (PAD) affects 8–12% of Americans over 65 and is associated with a major decline in functional status, increased myocardial infarction and stroke rates, and increased risk of ischemic amputation. Current treatment strategies for claudication have limitations. PACE is an NHLBI-sponsored, randomized, double-blind, placebo-controlled phase 2, exploratory clinical trial designed to assess safety and efficacy of autologous bone marrow–derived aldehyde dehydrogenase bright (ALDHbr) cells in PAD patients and to explore associated claudication physiologic mechanisms.
机译:背景动脉粥样硬化性外周动脉疾病(PAD)影响65岁以上的美国人中的8–12%,并且与功能状态的严重下降,心肌梗塞和中风发生率的增加以及缺血性截肢的风险增加有关。当前的lau行治疗策略有局限性。 PACE是一项由NHLBI赞助,随机,双盲,安慰剂对照的2期探索性临床试验,旨在评估自体骨髓源性醛脱氢酶亮(ALDHbr)细胞在PAD患者中的安全性和有效性,并探讨相关的lau行生理机制。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号